Optimization of Lyophilized Hyperacute Serum (HAS) as a Regenerative Therapeutic in Osteoarthritis
Hyperacute serum (HAS) is a blood derivative product that promotes the proliferation of various cell types and controls inflammation in vitro. The aim of this study is to investigate the regenerative potential of different formulations of HAS, including lyophilized and hyaluronic acid combined versi...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2021-07, Vol.22 (14), p.7496 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 14 |
| container_start_page | 7496 |
| container_title | International journal of molecular sciences |
| container_volume | 22 |
| creator | Olmos Calvo, Isabel Kuten-Pella, Olga Kramer, Karina Madár, Ágnes Takács, Szilvia Kardos, Dorottya Simon, Diána Erdö-Bonyár, Szabina Berki, Timea De Luna, Andrea Nehrer, Stefan Lacza, Zsombor |
| description | Hyperacute serum (HAS) is a blood derivative product that promotes the proliferation of various cell types and controls inflammation in vitro. The aim of this study is to investigate the regenerative potential of different formulations of HAS, including lyophilized and hyaluronic acid combined versions, to obtain a stable and standardized therapeutic in osteoarthritis (OA), which may be able to overcome the variability limitations of platelet-rich plasma (PRP). Primary human osteoarthritic chondrocytes were used for testing cellular viability and gene expression of OA-related genes. Moreover, a co-culture of human explants of cartilage, bone and synovium under inflammatory conditions was used for investigating the inflammatory control capacities of the different therapeutics. In this study, one formulation of lyophilized HAS achieved the high cell viability rates of liquid HAS and PRP. Gene expression analysis showed that HAS induced higher
expression than PRP. Cytokine quantification from supernatant fluids revealed that HAS treatment of inflamed co-cultures significantly reduced levels of IL-5, IL-15, IL-2, TNFα, IL-7 and IL-12. To conclude, lyophilized HAS is a stable and standardized therapeutic with high potential in joint regeneration. |
| doi_str_mv | 10.3390/ijms22147496 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8305834</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2555113153</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-d7c944c5739fad430663a24315b3443652ee130a7a7b139b0e964bcd44715c73</originalsourceid><addsrcrecordid>eNpdkd1rFDEUxYMo9kPffJaALy24muQmk8lLoRR1hYUFu-8hk7nbzTIzGZNMYfvXO6W1rD7dA_fH4RwOIR84-wJg2New77MQXGppqlfklEshFoxV-vWRPiFnOe8ZEyCUeUtOQApjuIBT0qzHEvrw4EqIA41bujrEcRe68IAtXR5GTM5PBektpqmnF8vr20vqMnX0F97hMH9LuEe62c1qxKkET8NA17lgdKnsUighvyNvtq7L-P75npPN92-bm-Vitf7x8-Z6tfBS12XRam-k9EqD2bpWAqsqcEICVw1ICZUSiByY0043HEzD0FSy8a2Umiuv4ZxcPdmOU9Nj63EoyXV2TKF36WCjC_bfzxB29i7e2xqYqkHOBhfPBin-njAX24fssevcgHHKViilOJ_zwIx--g_dxykNc7tHSqqqrg2bqc9PlE8x54TblzCc2cft7PF2M_7xuMAL_Hcs-AOywZVo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2554568890</pqid></control><display><type>article</type><title>Optimization of Lyophilized Hyperacute Serum (HAS) as a Regenerative Therapeutic in Osteoarthritis</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Olmos Calvo, Isabel ; Kuten-Pella, Olga ; Kramer, Karina ; Madár, Ágnes ; Takács, Szilvia ; Kardos, Dorottya ; Simon, Diána ; Erdö-Bonyár, Szabina ; Berki, Timea ; De Luna, Andrea ; Nehrer, Stefan ; Lacza, Zsombor</creator><creatorcontrib>Olmos Calvo, Isabel ; Kuten-Pella, Olga ; Kramer, Karina ; Madár, Ágnes ; Takács, Szilvia ; Kardos, Dorottya ; Simon, Diána ; Erdö-Bonyár, Szabina ; Berki, Timea ; De Luna, Andrea ; Nehrer, Stefan ; Lacza, Zsombor</creatorcontrib><description>Hyperacute serum (HAS) is a blood derivative product that promotes the proliferation of various cell types and controls inflammation in vitro. The aim of this study is to investigate the regenerative potential of different formulations of HAS, including lyophilized and hyaluronic acid combined versions, to obtain a stable and standardized therapeutic in osteoarthritis (OA), which may be able to overcome the variability limitations of platelet-rich plasma (PRP). Primary human osteoarthritic chondrocytes were used for testing cellular viability and gene expression of OA-related genes. Moreover, a co-culture of human explants of cartilage, bone and synovium under inflammatory conditions was used for investigating the inflammatory control capacities of the different therapeutics. In this study, one formulation of lyophilized HAS achieved the high cell viability rates of liquid HAS and PRP. Gene expression analysis showed that HAS induced higher
expression than PRP. Cytokine quantification from supernatant fluids revealed that HAS treatment of inflamed co-cultures significantly reduced levels of IL-5, IL-15, IL-2, TNFα, IL-7 and IL-12. To conclude, lyophilized HAS is a stable and standardized therapeutic with high potential in joint regeneration.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms22147496</identifier><identifier>PMID: 34299123</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adult ; Arthritis ; Biomedical materials ; Cartilage ; Cartilage diseases ; Cell culture ; Cell growth ; Cell viability ; Chondrocytes ; Chondrocytes - cytology ; Coculture Techniques ; Collagen (type I) ; Cytokines ; Explants ; Gene expression ; Healthy Volunteers ; Humans ; Hyaluronic acid ; Inflammation ; Interleukin 12 ; Interleukin 15 ; Interleukin 2 ; Interleukin 5 ; Interleukin 7 ; Middle Aged ; Older people ; Osteoarthritis ; Osteoarthritis - therapy ; Platelet-Rich Plasma - chemistry ; Regeneration ; Regenerative Medicine - standards ; Regression analysis ; Serum - chemistry ; Synovium ; Tumor necrosis factor-α</subject><ispartof>International journal of molecular sciences, 2021-07, Vol.22 (14), p.7496</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-d7c944c5739fad430663a24315b3443652ee130a7a7b139b0e964bcd44715c73</citedby><cites>FETCH-LOGICAL-c478t-d7c944c5739fad430663a24315b3443652ee130a7a7b139b0e964bcd44715c73</cites><orcidid>0000-0002-1827-1314 ; 0000-0002-5636-8643 ; 0000-0001-7886-0244</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305834/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305834/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34299123$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Olmos Calvo, Isabel</creatorcontrib><creatorcontrib>Kuten-Pella, Olga</creatorcontrib><creatorcontrib>Kramer, Karina</creatorcontrib><creatorcontrib>Madár, Ágnes</creatorcontrib><creatorcontrib>Takács, Szilvia</creatorcontrib><creatorcontrib>Kardos, Dorottya</creatorcontrib><creatorcontrib>Simon, Diána</creatorcontrib><creatorcontrib>Erdö-Bonyár, Szabina</creatorcontrib><creatorcontrib>Berki, Timea</creatorcontrib><creatorcontrib>De Luna, Andrea</creatorcontrib><creatorcontrib>Nehrer, Stefan</creatorcontrib><creatorcontrib>Lacza, Zsombor</creatorcontrib><title>Optimization of Lyophilized Hyperacute Serum (HAS) as a Regenerative Therapeutic in Osteoarthritis</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Hyperacute serum (HAS) is a blood derivative product that promotes the proliferation of various cell types and controls inflammation in vitro. The aim of this study is to investigate the regenerative potential of different formulations of HAS, including lyophilized and hyaluronic acid combined versions, to obtain a stable and standardized therapeutic in osteoarthritis (OA), which may be able to overcome the variability limitations of platelet-rich plasma (PRP). Primary human osteoarthritic chondrocytes were used for testing cellular viability and gene expression of OA-related genes. Moreover, a co-culture of human explants of cartilage, bone and synovium under inflammatory conditions was used for investigating the inflammatory control capacities of the different therapeutics. In this study, one formulation of lyophilized HAS achieved the high cell viability rates of liquid HAS and PRP. Gene expression analysis showed that HAS induced higher
expression than PRP. Cytokine quantification from supernatant fluids revealed that HAS treatment of inflamed co-cultures significantly reduced levels of IL-5, IL-15, IL-2, TNFα, IL-7 and IL-12. To conclude, lyophilized HAS is a stable and standardized therapeutic with high potential in joint regeneration.</description><subject>Adult</subject><subject>Arthritis</subject><subject>Biomedical materials</subject><subject>Cartilage</subject><subject>Cartilage diseases</subject><subject>Cell culture</subject><subject>Cell growth</subject><subject>Cell viability</subject><subject>Chondrocytes</subject><subject>Chondrocytes - cytology</subject><subject>Coculture Techniques</subject><subject>Collagen (type I)</subject><subject>Cytokines</subject><subject>Explants</subject><subject>Gene expression</subject><subject>Healthy Volunteers</subject><subject>Humans</subject><subject>Hyaluronic acid</subject><subject>Inflammation</subject><subject>Interleukin 12</subject><subject>Interleukin 15</subject><subject>Interleukin 2</subject><subject>Interleukin 5</subject><subject>Interleukin 7</subject><subject>Middle Aged</subject><subject>Older people</subject><subject>Osteoarthritis</subject><subject>Osteoarthritis - therapy</subject><subject>Platelet-Rich Plasma - chemistry</subject><subject>Regeneration</subject><subject>Regenerative Medicine - standards</subject><subject>Regression analysis</subject><subject>Serum - chemistry</subject><subject>Synovium</subject><subject>Tumor necrosis factor-α</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkd1rFDEUxYMo9kPffJaALy24muQmk8lLoRR1hYUFu-8hk7nbzTIzGZNMYfvXO6W1rD7dA_fH4RwOIR84-wJg2New77MQXGppqlfklEshFoxV-vWRPiFnOe8ZEyCUeUtOQApjuIBT0qzHEvrw4EqIA41bujrEcRe68IAtXR5GTM5PBektpqmnF8vr20vqMnX0F97hMH9LuEe62c1qxKkET8NA17lgdKnsUighvyNvtq7L-P75npPN92-bm-Vitf7x8-Z6tfBS12XRam-k9EqD2bpWAqsqcEICVw1ICZUSiByY0043HEzD0FSy8a2Umiuv4ZxcPdmOU9Nj63EoyXV2TKF36WCjC_bfzxB29i7e2xqYqkHOBhfPBin-njAX24fssevcgHHKViilOJ_zwIx--g_dxykNc7tHSqqqrg2bqc9PlE8x54TblzCc2cft7PF2M_7xuMAL_Hcs-AOywZVo</recordid><startdate>20210713</startdate><enddate>20210713</enddate><creator>Olmos Calvo, Isabel</creator><creator>Kuten-Pella, Olga</creator><creator>Kramer, Karina</creator><creator>Madár, Ágnes</creator><creator>Takács, Szilvia</creator><creator>Kardos, Dorottya</creator><creator>Simon, Diána</creator><creator>Erdö-Bonyár, Szabina</creator><creator>Berki, Timea</creator><creator>De Luna, Andrea</creator><creator>Nehrer, Stefan</creator><creator>Lacza, Zsombor</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1827-1314</orcidid><orcidid>https://orcid.org/0000-0002-5636-8643</orcidid><orcidid>https://orcid.org/0000-0001-7886-0244</orcidid></search><sort><creationdate>20210713</creationdate><title>Optimization of Lyophilized Hyperacute Serum (HAS) as a Regenerative Therapeutic in Osteoarthritis</title><author>Olmos Calvo, Isabel ; Kuten-Pella, Olga ; Kramer, Karina ; Madár, Ágnes ; Takács, Szilvia ; Kardos, Dorottya ; Simon, Diána ; Erdö-Bonyár, Szabina ; Berki, Timea ; De Luna, Andrea ; Nehrer, Stefan ; Lacza, Zsombor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-d7c944c5739fad430663a24315b3443652ee130a7a7b139b0e964bcd44715c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Arthritis</topic><topic>Biomedical materials</topic><topic>Cartilage</topic><topic>Cartilage diseases</topic><topic>Cell culture</topic><topic>Cell growth</topic><topic>Cell viability</topic><topic>Chondrocytes</topic><topic>Chondrocytes - cytology</topic><topic>Coculture Techniques</topic><topic>Collagen (type I)</topic><topic>Cytokines</topic><topic>Explants</topic><topic>Gene expression</topic><topic>Healthy Volunteers</topic><topic>Humans</topic><topic>Hyaluronic acid</topic><topic>Inflammation</topic><topic>Interleukin 12</topic><topic>Interleukin 15</topic><topic>Interleukin 2</topic><topic>Interleukin 5</topic><topic>Interleukin 7</topic><topic>Middle Aged</topic><topic>Older people</topic><topic>Osteoarthritis</topic><topic>Osteoarthritis - therapy</topic><topic>Platelet-Rich Plasma - chemistry</topic><topic>Regeneration</topic><topic>Regenerative Medicine - standards</topic><topic>Regression analysis</topic><topic>Serum - chemistry</topic><topic>Synovium</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Olmos Calvo, Isabel</creatorcontrib><creatorcontrib>Kuten-Pella, Olga</creatorcontrib><creatorcontrib>Kramer, Karina</creatorcontrib><creatorcontrib>Madár, Ágnes</creatorcontrib><creatorcontrib>Takács, Szilvia</creatorcontrib><creatorcontrib>Kardos, Dorottya</creatorcontrib><creatorcontrib>Simon, Diána</creatorcontrib><creatorcontrib>Erdö-Bonyár, Szabina</creatorcontrib><creatorcontrib>Berki, Timea</creatorcontrib><creatorcontrib>De Luna, Andrea</creatorcontrib><creatorcontrib>Nehrer, Stefan</creatorcontrib><creatorcontrib>Lacza, Zsombor</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Olmos Calvo, Isabel</au><au>Kuten-Pella, Olga</au><au>Kramer, Karina</au><au>Madár, Ágnes</au><au>Takács, Szilvia</au><au>Kardos, Dorottya</au><au>Simon, Diána</au><au>Erdö-Bonyár, Szabina</au><au>Berki, Timea</au><au>De Luna, Andrea</au><au>Nehrer, Stefan</au><au>Lacza, Zsombor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimization of Lyophilized Hyperacute Serum (HAS) as a Regenerative Therapeutic in Osteoarthritis</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2021-07-13</date><risdate>2021</risdate><volume>22</volume><issue>14</issue><spage>7496</spage><pages>7496-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Hyperacute serum (HAS) is a blood derivative product that promotes the proliferation of various cell types and controls inflammation in vitro. The aim of this study is to investigate the regenerative potential of different formulations of HAS, including lyophilized and hyaluronic acid combined versions, to obtain a stable and standardized therapeutic in osteoarthritis (OA), which may be able to overcome the variability limitations of platelet-rich plasma (PRP). Primary human osteoarthritic chondrocytes were used for testing cellular viability and gene expression of OA-related genes. Moreover, a co-culture of human explants of cartilage, bone and synovium under inflammatory conditions was used for investigating the inflammatory control capacities of the different therapeutics. In this study, one formulation of lyophilized HAS achieved the high cell viability rates of liquid HAS and PRP. Gene expression analysis showed that HAS induced higher
expression than PRP. Cytokine quantification from supernatant fluids revealed that HAS treatment of inflamed co-cultures significantly reduced levels of IL-5, IL-15, IL-2, TNFα, IL-7 and IL-12. To conclude, lyophilized HAS is a stable and standardized therapeutic with high potential in joint regeneration.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>34299123</pmid><doi>10.3390/ijms22147496</doi><orcidid>https://orcid.org/0000-0002-1827-1314</orcidid><orcidid>https://orcid.org/0000-0002-5636-8643</orcidid><orcidid>https://orcid.org/0000-0001-7886-0244</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2021-07, Vol.22 (14), p.7496 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8305834 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult Arthritis Biomedical materials Cartilage Cartilage diseases Cell culture Cell growth Cell viability Chondrocytes Chondrocytes - cytology Coculture Techniques Collagen (type I) Cytokines Explants Gene expression Healthy Volunteers Humans Hyaluronic acid Inflammation Interleukin 12 Interleukin 15 Interleukin 2 Interleukin 5 Interleukin 7 Middle Aged Older people Osteoarthritis Osteoarthritis - therapy Platelet-Rich Plasma - chemistry Regeneration Regenerative Medicine - standards Regression analysis Serum - chemistry Synovium Tumor necrosis factor-α |
| title | Optimization of Lyophilized Hyperacute Serum (HAS) as a Regenerative Therapeutic in Osteoarthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T06%3A53%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimization%20of%20Lyophilized%20Hyperacute%20Serum%20(HAS)%20as%20a%20Regenerative%20Therapeutic%20in%20Osteoarthritis&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Olmos%20Calvo,%20Isabel&rft.date=2021-07-13&rft.volume=22&rft.issue=14&rft.spage=7496&rft.pages=7496-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms22147496&rft_dat=%3Cproquest_pubme%3E2555113153%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2554568890&rft_id=info:pmid/34299123&rfr_iscdi=true |